MTF2 and thyroid gland carcinoma: The expression of PCL2 appeared to be different among the 33 tumor types, with lower than normal expressions in adrenocortical carcinoma (ACC), kidney Chromophobe (KICH), LAML, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD) and Thyroid carcinoma (THCA), and higher than normal expressions in diffuse large B-cell lymphoma (DLBC), esophageal cancer (ESCA), and head and neck squamous cell carcinoma (HNSC) (Fig. 1a).